Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex: a Prospective Observational Study
Sponsor
Seoul National University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05760560
Collaborator
(none)
52
18
Study Details
Study Description
Brief Summary
This study is a prospective observational study. A total 52 patients will be included in this study. We will observe the incidence of postoperative residual neuromuscular blockade in patients receiving sugammadex.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
52 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex: a Prospective Observational Study
Anticipated Study Start Date
:
Mar 2, 2023
Anticipated Primary Completion Date
:
Aug 31, 2023
Anticipated Study Completion Date
:
Aug 31, 2024
Outcome Measures
Primary Outcome Measures
- Postoperative residual neuromuscular blockade [On the arrival of PACU]
TOF ratio < 0.9
Eligibility Criteria
Criteria
Ages Eligible for Study:
19 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Patients undergoing elective surgery under general anesthesia.
-
American Society of Anesthesiologists grade 1, 2, or 3.
-
Aged >18 years
Exclusion Criteria:
-
Refusal to participate in the study
-
Body Mass Index < 18.5 kg/m2 or > 35 kg/m2
-
History of neuromuscular disease.
-
History of allergy to neuromuscular blockade
-
Scheduled to transfer to the intensive care unit
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Seoul National University Hospital
Investigators
- Principal Investigator: Chang-Hoon Koo, Seoul National University Bundang Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Chang-Hoon Koo,
Assistant professor,
Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT05760560
Other Study ID Numbers:
- TOF-Sugammadex
First Posted:
Mar 8, 2023
Last Update Posted:
Mar 8, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: